Imatinib Drug Market

ID: MRFR/Pharma/41096-HCR
200 Pages
Satyendra Maurya
Last Updated: April 06, 2026
Imatinib Drug Market Research Report By Therapeutic Application (Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumors, Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia), By Dosage Form (Tablets, Oral Solution, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals, Clinics, Homecare Settings) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Therapeutic Application (USD Billion)
      1. 4.1.1 Chronic Myeloid Leukemia
      2. 4.1.2 Gastrointestinal Stromal Tumors
      3. 4.1.3 Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    2. 4.2 Healthcare, BY Dosage Form (USD Billion)
      1. 4.2.1 Tablets
      2. 4.2.2 Oral Solution
      3. 4.2.3 Injectable
    3. 4.3 Healthcare, BY Distribution Channel (USD Billion)
      1. 4.3.1 Hospital Pharmacies
      2. 4.3.2 Retail Pharmacies
      3. 4.3.3 Online Pharmacies
    4. 4.4 Healthcare, BY End User (USD Billion)
      1. 4.4.1 Hospitals
      2. 4.4.2 Clinics
      3. 4.4.3 Homecare Settings
    5. 4.5 Healthcare, BY Region (USD Billion)
      1. 4.5.1 North America
        1. 4.5.1.1 US
        2. 4.5.1.2 Canada
      2. 4.5.2 Europe
        1. 4.5.2.1 Germany
        2. 4.5.2.2 UK
        3. 4.5.2.3 France
        4. 4.5.2.4 Russia
        5. 4.5.2.5 Italy
        6. 4.5.2.6 Spain
        7. 4.5.2.7 Rest of Europe
      3. 4.5.3 APAC
        1. 4.5.3.1 China
        2. 4.5.3.2 India
        3. 4.5.3.3 Japan
        4. 4.5.3.4 South Korea
        5. 4.5.3.5 Malaysia
        6. 4.5.3.6 Thailand
        7. 4.5.3.7 Indonesia
        8. 4.5.3.8 Rest of APAC
      4. 4.5.4 South America
        1. 4.5.4.1 Brazil
        2. 4.5.4.2 Mexico
        3. 4.5.4.3 Argentina
        4. 4.5.4.4 Rest of South America
      5. 4.5.5 MEA
        1. 4.5.5.1 GCC Countries
        2. 4.5.5.2 South Africa
        3. 4.5.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Novartis (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bristol-Myers Squibb (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Teva Pharmaceutical Industries (IL)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Mylan (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Sun Pharmaceutical Industries (IN)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 AstraZeneca (GB)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Pfizer (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Roche (CH)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    4. 6.4 US MARKET ANALYSIS BY DOSAGE FORM
    5. 6.5 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    6. 6.6 US MARKET ANALYSIS BY END USER
    7. 6.7 CANADA MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    8. 6.8 CANADA MARKET ANALYSIS BY DOSAGE FORM
    9. 6.9 CANADA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    10. 6.10 CANADA MARKET ANALYSIS BY END USER
    11. 6.11 EUROPE MARKET ANALYSIS
    12. 6.12 GERMANY MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    13. 6.13 GERMANY MARKET ANALYSIS BY DOSAGE FORM
    14. 6.14 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    15. 6.15 GERMANY MARKET ANALYSIS BY END USER
    16. 6.16 UK MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    17. 6.17 UK MARKET ANALYSIS BY DOSAGE FORM
    18. 6.18 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    19. 6.19 UK MARKET ANALYSIS BY END USER
    20. 6.20 FRANCE MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    21. 6.21 FRANCE MARKET ANALYSIS BY DOSAGE FORM
    22. 6.22 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    23. 6.23 FRANCE MARKET ANALYSIS BY END USER
    24. 6.24 RUSSIA MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    25. 6.25 RUSSIA MARKET ANALYSIS BY DOSAGE FORM
    26. 6.26 RUSSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    27. 6.27 RUSSIA MARKET ANALYSIS BY END USER
    28. 6.28 ITALY MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    29. 6.29 ITALY MARKET ANALYSIS BY DOSAGE FORM
    30. 6.30 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    31. 6.31 ITALY MARKET ANALYSIS BY END USER
    32. 6.32 SPAIN MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    33. 6.33 SPAIN MARKET ANALYSIS BY DOSAGE FORM
    34. 6.34 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    35. 6.35 SPAIN MARKET ANALYSIS BY END USER
    36. 6.36 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    37. 6.37 REST OF EUROPE MARKET ANALYSIS BY DOSAGE FORM
    38. 6.38 REST OF EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    39. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USER
    40. 6.40 APAC MARKET ANALYSIS
    41. 6.41 CHINA MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    42. 6.42 CHINA MARKET ANALYSIS BY DOSAGE FORM
    43. 6.43 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    44. 6.44 CHINA MARKET ANALYSIS BY END USER
    45. 6.45 INDIA MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    46. 6.46 INDIA MARKET ANALYSIS BY DOSAGE FORM
    47. 6.47 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    48. 6.48 INDIA MARKET ANALYSIS BY END USER
    49. 6.49 JAPAN MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    50. 6.50 JAPAN MARKET ANALYSIS BY DOSAGE FORM
    51. 6.51 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    52. 6.52 JAPAN MARKET ANALYSIS BY END USER
    53. 6.53 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    54. 6.54 SOUTH KOREA MARKET ANALYSIS BY DOSAGE FORM
    55. 6.55 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    56. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USER
    57. 6.57 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    58. 6.58 MALAYSIA MARKET ANALYSIS BY DOSAGE FORM
    59. 6.59 MALAYSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    60. 6.60 MALAYSIA MARKET ANALYSIS BY END USER
    61. 6.61 THAILAND MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    62. 6.62 THAILAND MARKET ANALYSIS BY DOSAGE FORM
    63. 6.63 THAILAND MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    64. 6.64 THAILAND MARKET ANALYSIS BY END USER
    65. 6.65 INDONESIA MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    66. 6.66 INDONESIA MARKET ANALYSIS BY DOSAGE FORM
    67. 6.67 INDONESIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    68. 6.68 INDONESIA MARKET ANALYSIS BY END USER
    69. 6.69 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    70. 6.70 REST OF APAC MARKET ANALYSIS BY DOSAGE FORM
    71. 6.71 REST OF APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    72. 6.72 REST OF APAC MARKET ANALYSIS BY END USER
    73. 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. 6.74 BRAZIL MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    75. 6.75 BRAZIL MARKET ANALYSIS BY DOSAGE FORM
    76. 6.76 BRAZIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    77. 6.77 BRAZIL MARKET ANALYSIS BY END USER
    78. 6.78 MEXICO MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    79. 6.79 MEXICO MARKET ANALYSIS BY DOSAGE FORM
    80. 6.80 MEXICO MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    81. 6.81 MEXICO MARKET ANALYSIS BY END USER
    82. 6.82 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    83. 6.83 ARGENTINA MARKET ANALYSIS BY DOSAGE FORM
    84. 6.84 ARGENTINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    85. 6.85 ARGENTINA MARKET ANALYSIS BY END USER
    86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DOSAGE FORM
    88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
    90. 6.90 MEA MARKET ANALYSIS
    91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DOSAGE FORM
    93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER
    95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DOSAGE FORM
    97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER
    99. 6.99 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    100. 6.100 REST OF MEA MARKET ANALYSIS BY DOSAGE FORM
    101. 6.101 REST OF MEA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    102. 6.102 REST OF MEA MARKET ANALYSIS BY END USER
    103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. 6.104 RESEARCH PROCESS OF MRFR
    105. 6.105 DRO ANALYSIS OF HEALTHCARE
    106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. 6.109 HEALTHCARE, BY THERAPEUTIC APPLICATION, 2024 (% SHARE)
    110. 6.110 HEALTHCARE, BY THERAPEUTIC APPLICATION, 2024 TO 2035 (USD Billion)
    111. 6.111 HEALTHCARE, BY DOSAGE FORM, 2024 (% SHARE)
    112. 6.112 HEALTHCARE, BY DOSAGE FORM, 2024 TO 2035 (USD Billion)
    113. 6.113 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    114. 6.114 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
    115. 6.115 HEALTHCARE, BY END USER, 2024 (% SHARE)
    116. 6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
    117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.2.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.2.4 BY END USER, 2025-2035 (USD Billion)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.3.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.3.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.3.4 BY END USER, 2025-2035 (USD Billion)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.4.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.4.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.4.4 BY END USER, 2025-2035 (USD Billion)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.5.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.5.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.5.4 BY END USER, 2025-2035 (USD Billion)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.6.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.6.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.6.4 BY END USER, 2025-2035 (USD Billion)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.7.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.7.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.7.4 BY END USER, 2025-2035 (USD Billion)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.8.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.8.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.8.4 BY END USER, 2025-2035 (USD Billion)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.9.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.9.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.9.4 BY END USER, 2025-2035 (USD Billion)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.10.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.10.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.10.4 BY END USER, 2025-2035 (USD Billion)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.11.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.11.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.11.4 BY END USER, 2025-2035 (USD Billion)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.12.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.12.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.12.4 BY END USER, 2025-2035 (USD Billion)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.13.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.13.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.13.4 BY END USER, 2025-2035 (USD Billion)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.14.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.14.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.14.4 BY END USER, 2025-2035 (USD Billion)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.15.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.15.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.15.4 BY END USER, 2025-2035 (USD Billion)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.16.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.16.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.16.4 BY END USER, 2025-2035 (USD Billion)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.17.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.17.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.17.4 BY END USER, 2025-2035 (USD Billion)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.18.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.18.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.18.4 BY END USER, 2025-2035 (USD Billion)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.19.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.19.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.19.4 BY END USER, 2025-2035 (USD Billion)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.20.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.20.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.20.4 BY END USER, 2025-2035 (USD Billion)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.21.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.21.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.21.4 BY END USER, 2025-2035 (USD Billion)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.22.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.22.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.22.4 BY END USER, 2025-2035 (USD Billion)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.23.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.23.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.23.4 BY END USER, 2025-2035 (USD Billion)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.24.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.24.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.24.4 BY END USER, 2025-2035 (USD Billion)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.25.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.25.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.25.4 BY END USER, 2025-2035 (USD Billion)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.26.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.26.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.26.4 BY END USER, 2025-2035 (USD Billion)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.27.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.27.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.27.4 BY END USER, 2025-2035 (USD Billion)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.28.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.28.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.28.4 BY END USER, 2025-2035 (USD Billion)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.29.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.29.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.29.4 BY END USER, 2025-2035 (USD Billion)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
      2. 7.30.2 BY DOSAGE FORM, 2025-2035 (USD Billion)
      3. 7.30.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      4. 7.30.4 BY END USER, 2025-2035 (USD Billion)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Healthcare Market Segmentation

Healthcare By Therapeutic Application (USD Billion, 2025-2035)

  • Chronic Myeloid Leukemia
  • Gastrointestinal Stromal Tumors
  • Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Healthcare By Dosage Form (USD Billion, 2025-2035)

  • Tablets
  • Oral Solution
  • Injectable

Healthcare By Distribution Channel (USD Billion, 2025-2035)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Healthcare By End User (USD Billion, 2025-2035)

  • Hospitals
  • Clinics
  • Homecare Settings